Drug Profile
Angiotensin 1 7 - Constant Therapeutics
Alternative Names: TXA-127; USB-002Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Tarix Orphan; Tarix Pharmaceuticals
- Developer Constant Therapeutics; Tarix Orphan; Tarix Pharmaceuticals; Unigene Laboratories; US Biotest Inc
- Class Angiotensins; Antihypertensives; Antiretrovirals; Peptide hormones; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Proto-oncogene protein c-mas-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Duchenne muscular dystrophy; SARS-CoV-2 acute respiratory disease; Stroke
- Preclinical Acute lung injury
- No development reported Amyotrophic lateral sclerosis; Epidermolysis bullosa; Epidermolysis bullosa dystrophica; Limb girdle muscular dystrophies; Marfan syndrome; Muscular dystrophies
- Discontinued Adult respiratory distress syndrome; HIV infections; Peripheral vascular disorders; Pulmonary arterial hypertension; Stem cell engraftment; Thrombocytopenia
Most Recent Events
- 31 Dec 2023 Vanderbilt University Medical Center completes a phase II/III clinical trials in COVID-2019 infections in USA (IV) (NCT04924660)
- 29 Nov 2023 Phase-II clinical trials in Stroke in Israel (SC) (NCT06135103)
- 31 Aug 2023 Phase-II clinical trials in Duchenne muscular dystrophy (Treatment-experienced, In adults, In adolescents) in Israel (SC) (NCT06013839)